Immunic Inc. (IMUX) Prices 2.18M Share Common Stock Offering at $11.40/Each
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/3/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Equities close higher as softer jobs data quiets rate-hike expectations
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock
June 10, 2020 9:17 AM EDTNEW YORK, June 10, 2020 /PRNewswire/ --Â Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the pricing of its previously announced public offering for the offering of 2,175,000 shares of common stock of the Company at a price to the public of $11.40Â per share, for aggregate gross proceeds to the Company of approximately $25 million, before deducting the fees and estimated offering expenses payable by the Company. The offering is expected to close on or about June 12,... More
Immunic, Inc. Announces Proposed Public Offering of Common Stock
June 9, 2020 7:39 PM EDTNEW YORK, June 9, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced it has commenced a public offering of shares of its common stock.
Immunic intends to use the proceeds from the offering to fund the ongoing clinical development of the Company's three small molecule products: IMU-838, IMU-935 and IMU-856, and for other general corporate purposes, including to investigate IMU-838, the Company's lead asset, as a potential oral treatment... More
